Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO) GI
Jan 21, 2023
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in
metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
El-Khoueiry, et al.
Filter by
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society of Gynecologic Oncology (SGO)
Mar 27, 2023
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab(anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer
Bockorny B, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Connective Tissue Oncology Society (CTOS)
Nov 18, 2022
A Phase IA/IB study of Botensilimab, a novel innate/adaptive immune activator, plus Balstilimab for the treatment of patients with sarcoma
Wilky, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 12, 2022
Botensilimab, a novel innate/adaptive immune activator with balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors
Wilky, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 11, 2022
Botensilimab, a novel Fc-enhanced anti-CTLA-4 antibody enhances T cell: APC functionality and promotes superior anti-tumor immunity
Levey, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Clinical Cancer Research
Jul 1, 2022
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny B, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 29
- Jul 2, 2022
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer.
Bullock, et al.
AGEN1571 (ILT2 Antagonist)
American Association for Cancer Research (AACR)
Apr 8
- Apr 12, 2022
AGEN1571 is a novel high-affinity ILT2 antagonist antibody that promotes adaptive and innate immune responses.
Udartseva, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Journal of Clinical Oncology
Dec 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O’Malley, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
Identification and characterization of an allogeneic iNKT-CAR targeting BCMA.
Michelet, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results.
El-Khoueiry, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product.
Purbhoo, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 10
- Nov 14, 2021
AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models.
Yigit, et al.
MK-4830 (ILT4 Antagonist)
Clinical Cancer Research
Oct 1, 2021
First-in-Class Anti-immunoglobulin – like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu, et al.
Balstilimab (PD-1 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
Balstilimab (PD-1 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).
O’Malley, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 16
- Sep 21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028).
Randall, et al.
Balstilimab (PD-1 Antagonist)
Gynecologic Oncology
Aug 25, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
Future Oncology
Aug 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 3
- Jun 7, 2021
Differentiated Activity Profile for the PD-1 Inhibitor Balstilimab.
C.Joyce, et al.
AGEN2373 (CD137 Agonist)
American Society of Clinical Oncology (ASCO)
Jun 3
- Jun 7, 2021
Initial Findings of the First-in-human Phase I Study of AGEN2373, a Conditionally Active CD137 Agonist Antibody, in Patients (pts) With Advanced Solid Tumors.
Tolcher, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 9
- Apr 14, 2021
Fc-enhanced anti-CTLA-4 Antibody, AGEN1181: New Mechanistic Insights for Potent Antitumor Immunity and Combination Potential in Treatment-resistant Solid Tumors.
Tanne, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 9
- Apr 14, 2021
Characterization of The Pharmacodynamic Activity of AGEN1181, an Fc-enhanced CTLA-4 Antibody, Alone and in Combination With the PD-1 Antibody Balstilimab.
Shapiro, et al.
Balstilimab (PD-1 Antagonist)
SGO 2021 Virtual Annual Meetings on Women’s Cancer Abstracts
Mar 19
- Mar 22, 2021
RaPiDS (GOG-3028): A Randomized Phase II Studyof Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)
Oncogene
Jan 26, 2021
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.
Grossman, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Pseudoprogression (PSP) Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer.
O’Malley, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing.
Burcu, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822).
Perez, et al.
AGEN1327 (TIGIT Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity.
Ward, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy.
O’Day, et al.
VISION
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro.
Pabla, et al.
AGEN2373 (CD137 Agonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects.
Galand, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials.
O’Malley, et al.
Balstilimab (PD-1 Antagonist)
European Society for Medical Oncology (ESMO) Virtual
Sep 19
- Sep 21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4)for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials .
O’Malley, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Jun 22
- Jun 24, 2020
Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors.
Tanne, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
May 29
- May 31, 2020
AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies.
O’Day, et al.
VISION
AI Powered Drug Discovery and Manufacturing (AIDM)
Feb 27
- Feb 28, 2020
Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors.
Pabla, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan, et al.
Balstilimab (PD-1 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
Single-agent Activity of a Novel PD-1 Inhibitor, AGEN2034, in Recurrent Ovarian Cancer.
O’Malley, et al.
VISION
Society for Immunotherapy of Cancer (SITC)
Nov 6
- Nov 10, 2019
Driving T cell Dysfunction in Vitro for Rational Immunotherapy Design.
Joyce, et al.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Frontiers in Immunology
Oct 22, 2019
TCR Fingerprinting and Off-Target Peptide Identification.
Karapetyan, et al.
Zalifrelimab (CTLA-4 Antagonist)
Journal for ImmunoTherapy of Cancer
Aug 8, 2019
Angiosarcoma Patients Treated with Immune Checkpoint Inhibitors: A Case Series of Seven Patients from a Single Institution.
Florou, et al.
Frontiers in Immunology
Aug 7, 2019
Mutation-Derived Neoantigens for Cancer Immunotherapy.
Castle, et al.
AGEN1327 (TIGIT Antagonist)
American Association for Cancer Research (AACR)
Mar 29
- Apr 3, 2019
FcgR Co-Engagement by Anti-TIGIT Monoclonal Antibodies Enhances T cell Functionality and Antitumor Immune Responses.
Chand, et al.
AGEN2373 (CD137 Agonist)
Society for Immunotherapy of Cancer (SITC)
Nov 7
- Nov 11, 2018
AGEN2373 is a Conditionally-Active Agonist Antibody Targeting the Co-Stimulatory Receptor CD137 for the Treatment of Human Malignancies.
Galand, et al.
Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 19
- Oct 23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.
Coward, et al.
Balstilimab (PD-1 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 19
- Oct 23, 2018
Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer.
Drescher, et al.
Balstilimab (PD-1 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 19
- Oct 23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors.
Coward, et al.
AGEN1327 (TIGIT Antagonist)
Cancer Cell
Jun 11, 2018
Selective FcgR Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Cancer Cell
Jun 11, 2018
Selective FcgR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 1
- Jun 5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN1884, an Anti-CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies: Dose Selection for Combination with PD-1 Blockade.
Wilky, et al.
Balstilimab (PD-1 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 1
- Jun 5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation.
Moore, et al.
INCAGN2385 (LAG-3 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies.
Savitsky, et al.
INCAGN2390 (TIM-3 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3.
Waight, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors.
de Souza, et al.
Balstilimab (PD-1 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors.
de Souza, et al.
Zalifrelimab (CTLA-4 Antagonist)
PLOS
Apr 4, 2018
Toxicological and Pharmacological Assessment of AGEN1884, a Novel Human IgG1 anti-CTLA-4 Antibody.
Gombos, et al.
Balstilimab (PD-1 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 12, 2017
AGEN2034, a Novel anti-PD-1 Antibody that Combines Effectively With CTLA-4 Pathway Blockade to Enhance T Cell Activity.
Chand, et al.
Zalifrelimab (CTLA-4 Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 12, 2017
Characterization of the anti-CTLA-4 Antibody AGEN1884, Including Toxicology and Pharmacology Assessments in Non-human Primates.
Gombos, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 2
- Jun 6, 2017
Phase 1, Open-Label, Multiple-Ascending-Dose Trial of AGEN1884, an Anti–CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies.
Wilky, et al.
INCAGN1876 (GITR Agonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
INCAGN1876, a Unique GITR Agonist Antibody That Facilitates GITR Oligomerization.
Gonzalez, et al.
INCAGN1949 (OX40 Agonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
INCAGN1949, an Anti-OX40 Antibody With an Optimal Agonistic Profile and the Ability to Selectively Deplete Intratumoral Regulatory T Cells.
Gonzalez, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 1
- Apr 5, 2017
AGEN1884, an IgG1 anti-CTLA-4 Antibody, Combines Effectively with PD-1 Blockade in Primary Human T Cell Assays and in a Non-human Primate Pharmacodynamic (PD) Model.
Drouin, et al.
AGEN2373 (CD137 Agonist), INCAGN1876 (GITR Agonist), INCAGN1949 (OX40 Agonist)
Human Antibodies
Jan 1, 2017
Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities
Waight, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Sep 15, 2016
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
AGEN1884 and AGEN2041: Two Functionally Distinct anti-CTLA-4 Antagonist Antibodies.
Drouin, et al.
INCAGN1876 (GITR Agonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
A Novel Agonist Antibody (INCAGN01876) That Targets the Costimulatory Receptor GITR.
Gonzalez, et al.
INCAGN1949 (OX40 Agonist)
American Association for Cancer Research (AACR)
Apr 16
- Apr 20, 2016
INCAGN01949: A Novel Anti-OX40 Agonist Antibody With the Potential to Enhance Tumor Specific T-cell Responsiveness, While Selectively Depleting Intratumoral Regulatory T Cells.
Gonzalez, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Nov 17, 2011
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children.
RTS,S Clinical Trials Partnership, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Nov 3, 2011
Safety and Immunogenicity of Long HSV-2 Peptides Complexed with rhHsc70 in HSV-2 Seropositive Persons.
Wald, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Nov 3, 2011
A Heat Shock Protein Based Polyvalent Vaccine Targeting HSV-2: CD4(+) and CD8(+) Cellular Immunity and Protective Efficacy.
Mo, et al.
QS-21 STIMULON™ Adjuvant
The Lancet Infectious Diseases
Oct 1, 2011
Safety and Efficacy of the RTS,S/AS01E Candidate Malaria Vaccine Given With Expanded-Programme-On-Immunisation Vaccines: 19 Month Follow-Up of a Randomised, Open-Label, Phase 2 Trial.
Asante, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Aug 11, 2011
Four Year Immunogenicity of the RTS,S/AS02(A) Malaria Vaccine in Mozambican Children During a Phase IIb Trial.
Aide, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Infectious Diseases
Jul 1, 2011
Effect of the Pre-Erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children.
Bejon, et al.
QS-21 STIMULON™ Adjuvant
Expert Review of Vaccines
Apr 1, 2011
Recent Clinical Experience With Vaccines Using MPL- And QS-21-Containing Adjuvant Systems.
Garçon, et al.
QS-21 STIMULON™ Adjuvant
Kidney International
Feb 1, 2010
Rapid, Enhanced, and Persistent Protection of Patients with Renal Insufficiency by AS02(V)-Adjuvanted Hepatitis B Vaccine.
Surquin, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Infectious Diseases
Nov 1, 2009
Synthetic Malaria Peptide Vaccine Elicits High Levels of Antibodies in Vaccinees of Defined HLA Genotypes.
Nardin, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Dec 11, 2008
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants.
Abdulla, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Dec 11, 2008
Efficacy of RTS,S/AS01E Vaccine Against Malaria in Children 5 to 17 Months of Age.
Bejon, et al.
QS-21 STIMULON™ Adjuvant
Expert Opinion on Biological Therapy
Jun 12, 2008
Cancer Immunotherapy Targeting Tumour-Specific Antigens: Towards a New Therapy for Minimal Residual Disease.
Brichard, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Mar 4, 2008
Vaccine Adjuvant Systems Containing Monophosphoryl Lipid A and QS21 Induce Strong and Persistent Humoral and T Cell Responses Against Hepatitis B Surface Antigen in Healthy Adult Volunteers.
Vandepapelière, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Jul 15, 2005
Induction of Humoral and CD8+ T Cell Responses are Required for Protection Against Lethal Ebola Virus Infection.
Warfiled, et. al.
QS-21 STIMULON™ Adjuvant
Clinical Cancer Research
May 1, 2002
T-cell Responses Against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-Stimulating Factor, and QS-21 as Immunological Adjuvants.
Schaed, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Jul 16, 2001
Three Double-Blind, Randomized Trials Evaluating the Safety and Tolerance of Different Formulations of the Saponin Adjuvant QS-21.
Waite, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Feb 28, 2001
QS-21 Promotes an Adjuvant Effect Allowing for Reduced Antigen Dose During HIV-1 Envelope Subunit Immunization in Human.
Evans, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Feb 15, 2001
Oral QS-21 Requires Early IL-4 Help for Induction of Mucosal and Systemic Immunity.
Boyaka, et al.
QS-21 STIMULON™ Adjuvant
Vaccine
Nov 12, 1999
Comparison of the Effect of Different Immunological Adjuvants on the Antibody and T Cell Response to Immunization with MUC1-KLH and GD3-KLH Conjugate Cancer Vaccines.
Kim, et al.
QS-21 STIMULON™ Adjuvant
Journal of Virology
Jun 1, 1998
Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated With QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes.
Sasaki, et al.
QS-21 STIMULON™ Adjuvant
New England Journal of Medicine
Jan 9, 1997
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria. RTS,S Malaria Vaccine Evaluation Group.
Stoute, et al.
QS-21 STIMULON™ Adjuvant
Carbohydrate Research
Jan 4, 1996
Structure of the saponin adjuvant QS-21 and its Base-Catalyzed Isomerization Product by 1H and Natural Abundance 13C NMR Spectroscopy.
Jacobsen, et al.
QS-21 STIMULON™ Adjuvant
Critical Reviews in Therapeutic Drug Carrier Systems
Jan 1, 1996
Saponins as Vaccine Adjuvants.
Kensil, CR.
QS-21 STIMULON™ Adjuvant
Cancer Research
Jul 1, 1995
GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients After Administration With Immunological Adjuvant QS-21.
Helling, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Apr 15, 1992
Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses.
Newman, et al.
QS-21 STIMULON™ Adjuvant
The Journal of Immunology
Jan 15, 1991
Separation and Characterization of Saponins With Adjuvant Activity From Quillaja Saponaria Molina Cortex.
Kensil, CR.